Drug profile · INN
ribavirin
RIBAVIRIN BIOPARTNERS
ribavirin (RIBAVIRIN BIOPARTNERS) is a inosine-5'-monophosphate dehydrogenase 1 inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — ribavirin
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- ORAL
- Patents
- 4
- Programs
- 8
- Data quality
- 0.89
Quick answer
ribavirin (RIBAVIRIN BIOPARTNERS) is a inosine-5'-monophosphate dehydrogenase 1 inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Inosine-5'-monophosphate dehydrogenase 1 inhibitor
Primary target: Inosine-5'-monophosphate dehydrogenase 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 8664273
Treatment of hepatitis C virus with telaprevir (VX-950) in patients non-responsive to treatment with pegylated interferon-alpha 2A/2B and ribavirin
granted -
US 7410979
Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
granted -
WO 03105839
VERWENDUNG VON RIBAVIRIN ZUR HERSTELLUNG EINER PHARMAZEUTISCHEN ZUSAMMENSETZUNG GEGEN BUNYAVIRIDAE
expired -
CA 2470342
GRANULAT DE RIBAVIRINE POUR LA PRODUCTION DE COMPRIMES PELLICULES
expired
Frequently asked questions
What is ribavirin?
ribavirin (RIBAVIRIN BIOPARTNERS) is a inosine-5'-monophosphate dehydrogenase 1 inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ribavirin?
RIBAVIRIN BIOPARTNERS is a marketed brand name for ribavirin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ribavirin?
ribavirin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.